Skip to main content
. Author manuscript; available in PMC: 2014 Jan 23.
Published in final edited form as: Nature. 2001 Sep 13;413(6852):165–171. doi: 10.1038/35093109

Figure 2.

Figure 2

RMA cells expressing NKG2D ligands are rejected by NK cells and CD8 T cells in syngeneic mice. B6 (a) or B6-Rag1−/− (b) mice were pretreated with the indicated antibodies and inoculated subcutaneously with the indicated numbers of RMA transductants or RMA/S cells. In instances where tumors grew in some but not all mice, the fractions are indicated in the panels. Data are representative of four experiments. c, Levels of NKG2D ligands determined by staining with fluorescently labeled tetrameric NKG2D. Tumor cell transductants, the YAC-1 lymphoma and the Sa1N fibrosarcoma are compared. d, The anti tumor response depends on Rae1β levels. Survival of B6 mice that had been inoculated with 1×105 RMA cells, or RMA cells expressing high (Rae1hi ) or intermediate (Rae1int ) levels of Rae1β. Terminally moribund mice were sacrificed. Data are representative of two experiments.